Projects We Have Joined

Efforts to Improve Access to Medicines Mainly in Developing Countries

City Cancer Challenge Foundation (C/Can)

News Release: Chugai Announces New Partnership with City Cancer Challenge Foundation to Enhance the Quality of Patient-Centered Cancer Care in Yangon (July. 20, 2020) [PDF 197KB]

C/Can is a city-based partnership initiative that aims to improve access to quality cancer care in countries around the world by transforming the way stakeholders from the public and private sectors collectively design, plan, and implement cancer solutions.
Chugai participates in the project in Myanmar, with the aim to develop disseminate and solidify high-quality treatment guidelines through the introduction of a multidisciplinary, evidence-based clinical decision-making approach that is collaborated by medical personnel based on an analysis of the actual situation in the city.

AMR Action Fund

Infectious diseases caused by the ineffectiveness of existing antimicrobial drugs, or antimicrobial resistance (AMR), are increasing rapidly throughout the world, and the discovery of new antimicrobial agents is urgently needed. Without action, it is estimated that the number of deaths due to antimicrobial resistance will rise to 10 million per year by 2050*.

AMR Action Fund is an initiative by over 20 leading biopharmaceutical companies, including Chugai, who have pledged to invest nearly US$1 billion toward commercializing two to four new antibiotics by 2030. The fund will invest in and provide technical assistance to small biotech companies and others developing innovative antibacterial treatments. The fund will forge partnerships with research institutions, philanthropic organizations, development banks, and multilateral organizations to strengthen and accelerate antibiotic development. (July 1, 2020)

AMR Action Fund

  • *Source: Antimicrobial Resistance in G7 Countries and Beyond, OECD report. September 2015

WFH Humanitarian Aid Program

News Release: Together with Roche, Chugai Pledges to Extend Commitment to the World Federation of Hemophilia Humanitarian Aid Program to 2028 (May. 10, 2022) [PDF 311KB]

News Release: Together with Roche, Chugai Joins the World Federation of Hemophilia Humanitarian Aid Program (Feb. 06, 2019) [PDF 178KB]

WFH Humanitarian Aid Program is a landmark initiative leading the effort to improve access to care and treatment for people with inherited bleeding disorders in developing countries where access to treatment is limited.
Roche Group’s prophylactic treatment will be provided to the WFH Humanitarian Aid Program to continue to treat as many as 1,000 people with hemophilia A in locations where there is little to no access to treatment. Also, funding will be conducted to deliver the WFH Program’s integrated care development training to ensure that local infrastructure and medical expertise are available to optimize and appropriately use the donated treatment. Chugai, the originator of the novel prophylactic treatment, will also continue its contribution as a member of the Roche Group. The partnership, which was originally formed by Roche and the WFH in February 2019, marked the first time that patients in developing countries had received access to a prophylactic treatment. In 2022, our prophylactic treatment contributed to treat 1,100 people as non-factor replacement therapy.

WFH Humanitarian Aid Program IMPACT REPORT 2022

Access Accelerated

News Release: Chugai to Join Global Initiative for Addressing Rise of Non-Communicable Diseases in Low and Lower-Middle Income Countries (Jan. 18, 2017) [PDF 71KB]

To work on the United Nations Sustainable Development Goal to reduce premature deaths from non-communicable diseases (NCDs) by one-third by 2030, 22 leading global biopharmaceutical companies launched Access Accelerated. It is a global initiative to advance access to NCD prevention information, diagnosis and care in low and middle-income countries.

Access Accelerated

Global Health Innovative Technology Fund (GHIT Fund)

News Release: Participation in the Global Health Innovative Technology Fund (GHIT Fund) (Dec. 24, 2014) [PDF 120KB]

GHIT Fund is a public-private partnership to support research and development of pharmaceuticals, vaccines and diagnostics for serious diseases in developing countries. It utilizes Japan’s medical technology, innovation and knowledge more directly.


  • Like
  • Post
  • LINE it!
  • E-mail

Global Health

Back to top